Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | F10 | P00742 | 6/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432752 | 0.93 | HPGD (0.56) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5427134 | 0.90 | HPGD (0.57) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL4746829 | 0.86 | F10 (0.66) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL4747313 | 0.86 | RAB9A (0.65) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL4744626 | 0.85 | RAB9A (0.67) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5435276 | 0.85 | F10 (0.64) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5432482 | 0.83 | RAB9A (0.70) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5434208 | 0.83 | NPC1 (0.66) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5428989 | 0.80 | NPC1 (0.54) | HPGDNPC1SMN1; SMN2TSHRRAB9A | |
| SCHEMBL5434254 | 0.80 | HPGD (0.54) | HPGDNPC1SMN1; SMN2TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | HPGD 1815/4885NPC1 4319/4885SMN1; SMN2 2952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.